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Background: Trends in the management of renovascular hypertension were evaluated by using a representative national
database to determine whether a shift in treatment technology and outcomes has occurred.
Methods: Clinical information regarding the treatment of renovascular hypertension in 5433 patients from 1988 to 2001
was derived from the Nationwide Inpatient Sample (NIS) database. Patients were classified into 3 groups: combined
aortic and renal revascularization, isolated renal revascularization, and catheter-based procedures (angioplasty with or
without stenting). Population-based trends were determined by using sampling weights for each year to estimate the total
number of each intervention in the United States. Outcomes were compared using multivariate logistic regression analysis
for risk-adjustment.
Results: A 73% decrease in combined aortic and renal revascularizations (P  .033) and a 56% decrease in isolated renal
revascularizations (P < .001) occurred during the study period. Catheter-based procedures have increased 173% from 0.4
to 1.1 procedures per 100,000 adults during this same time period (P < .001). Predictors favoring catheter-based
treatment were admission acuity, increasing age, nonwhite race, and high socioeconomic status. Predictors of mortality
for all 3 treatment groups included increasing age, emergent admission, and nonwhite race.
Conclusions: A significant change in the management of patients with renovascular hypertension has occurred, with a shift
towards less invasive catheter-based interventions. A better understanding of the diffusion of this technology in the
treatment of individuals with renovascular hypertension will influence the training and distribution of future vascular
specialists responsible for these patients. ( J Vasc Surg 2004;40:717-23.)Renal artery stenosis is the most common form of
surgically correctable hypertension and is often found in
association with other forms of arteriosclerotic disease.1
Renal artery stenotic lesions exceeding 70% have been
found in up to one fifth of patients referred for coronary
angiography, and as many as a quarter of these patients have
bilateral occlusive disease.2,3 Left untreated, such advanced
disease progresses approximately 5% per year.3 Current
indications for revascularization of renal artery arterioscle-
rotic lesions include unilateral stenosis with asymmetric
perfusion of renal parenchyma, severe bilateral renal artery
stenosis, renovascular hypertension refractory to medical
therapy, or accelerating or malignant renovascular hyper-
tension. Invasive treatment of these lesions has been sug-
gested to preserve renal parenchyma and lessen hyperten-
sive risks in a cost-justified manner, compared with longer
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doi:10.1016/j.jvs.2004.07.029use of potent antihypertensive medications that may mask
disease progression with eventual loss of renal function and
renal failure.4-6
Arteriosclerotic renal artery stenosis has been treated
traditionally by open surgical revascularization, including
renal artery bypass or endarterectomy. These procedures
have often taken place during concomitant vascular recon-
structions for aortic aneurysmal or aortoiliac occlusive dis-
ease. However, catheter-based management of renal arte-
riosclerotic occlusive disease has gained favor. In a
randomized trial of percutaneous transluminal renal angio-
plasty (PTRA) versus surgery, Weibull et al7 reported sim-
ilar arterial patency and lesser mortality and morbidity rates
for PTRA compared with open revascularization. Never-
theless, others have reported poorer outcomes following
catheter-based treatment, including one group who noted
that 56% of patients undergoing PTRA subsequently re-
quired surgery.8 Operative mortality for surgical revascu-
larization has been reported from 0% to 9% for isolated
renal artery revascularization and from 3% to 20% in pa-
tients undergoing combined aortic and renal revasculariza-
tion.1,8-14 Although most centers report mortality rates for
PTRA and percutaneous transluminal renal stenting of
approximately 1%, some early reports have cited rates as
high as 4.8%.8,15-20 It is unclear whether the reported
outcomes are comparable across the United States. The717
5,000
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catheter-based therapy in the management of arterioscle-
rotic renal artery disease.
METHODS
Data source. The Nationwide Inpatient Sample (NIS)
is a 20% stratified random sample of all hospital discharges
in the United States. It is maintained by the Agency for
Healthcare Research and Quality as part of the Healthcare
Cost and Utilization Project.21 Patients studied included
those discharged during years 1988 to 2001 with an Inter-
national Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) code for renovascular hyperten-
sion (405.01, 405.11, or 405.91) and a concomitant code
for renal artery arteriosclerosis (440.1). Exclusion criteria
were age less than 20 years and a code for vascular trauma
(902.xx). Patients in this population were then subdivided
into 3 treatment groups. Group I, combined aortic and
renal revascularization, included patients with codes for
renal artery revascularization (38.1, 38.10, 38.16, 38.3,
38.30, 38.36, 38.4, 38.40, 38.46, 39.24, 55.4, 55.5,
55.51, 55.52, and 55.54) as well as codes for aortic and
aortoiliac revascularization (38.14, 38.34, 38.44, and
39.25). Group II, isolated renal revascularization, included
patients with codes for renal artery revascularization with-
out codes for aortoiliac revascularization. Group III, angio-
plasty and stenting, included patients with no surgical
revascularization codes and a code for catheter-based revas-
cularization (39.50, 39.59, and 39.90).
Outcome variables. Factors favoring performance of
angioplasty and stenting were identified to evaluate pat-
terns in allocation of therapeutic resources. The primary
outcome was in-hospital mortality. Secondary outcomes
assessed to ascertain changes in resource use included
length of stay (LOS), average hospital charge, and unfavor-
able discharge (to any location other than home).
Statistical analysis. Univariate analyses, using 2 test-
ing, were performed to assess differences over time in rates
Table I. Patient demographics
Patient characteristics
Aortic and
renal
revascularization
Total no. of patients 561
Age (y, mean  SD) 66 9
Female sex 56% (312)
Nonwhite race 6.4% (26)
Median local annual income rank*
(mean  SD)
2.44  1.06
Urgent admission 19% (95)
Emergent admission 8% (41)
Chronic renal disease 0.5% (3)
Diabetes mellitus 7% (38)
Chronic obstructive pulmonary disease 18% (99)
History of myocardial infarction 4% (22)
Mortality 5% (29)
Unfavorable discharge 28% (155)
*Median local annual income was ranked into 4 levels: 1, $25,000; 2, $2of angioplasty and stenting, mortality, LOS, hospital
charges, and unfavorable discharge. For modeling pur-
poses, calendar years were divided into 3 time periods:
1988 to 1992, 1993 to 1997, and 1998 to 2001. Race was
analyzed as a dichotomous variable: white versus nonwhite.
Geographic region was classified into Northeast, Midwest,
South, and West as defined by the US Census Bureau.
Comorbid diseases were used as a marker of case-mix in
accordance with previously established standards.22-24
True population-based rates were obtained by using sam-
pling weights to find the estimated number of total proce-
dures performed each year in the United States. This esti-
mate was then divided by the total adult population for
each year to approximate true population-based rates. Mul-
tivariate analyses of predictors of catheter-based treatment,
mortality, and unfavorable discharge were performed by
multiple logistic regression. P  .05 was considered signif-
icant. SPSS Version 11.0 (Chicago, Ill) was used for all
statistical analyses.
RESULTS
Patient characteristics. In total, 10,320 patients, dis-
charged from 1988 to 2001, were included in the NIS
database with a diagnostic code for renovascular hyperten-
sion and renal artery arteriosclerosis, and 5,433 underwent
an intervention. Of these patients, 561 underwent aortic
and renal revascularization, 976 underwent isolated renal
revascularization, and 3,896 underwent renal artery angio-
plasty and stenting (Table I). The mean age was 66 9 and
63 12 years for combined aortic and renal reconstruction
and isolated renal reconstructions, respectively, compared
with 67 12 years for renal artery angioplasty and stenting
(P .001). Patients undergoing combined aortic and renal
reconstructions and isolated renal reconstructions experi-
enced emergent admissions (8% and 9%, respectively) and
urgent admissions (19% and 18%, respectively) significantly
less often than patients undergoing angioplasty and stent-
ing (P  .001).
Isolated
renal
revascularization
Angioplasty and
stenting P
976 3896
63  12 67  12 .001
62% (605) 61% (2365) .038
5.4% (35) 10.0% (266) .001
2.36  1.07 2.60  1.07 .001
18% (161) 28% (1000) .001
9% (79) 18% (642) .001
0.8% (8) 0.6% (25) .767
10% (93) 14% (539) .001
9% (84) 8% (296) .001
5% (46) 5% (210) .276
2% (21) 1% (30) .001
17% (161) 9% (346) .001
to $35,000; 3, $35,001 to $45,000; 4, $45,000.
is ove
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charge diagnosis of renovascular hypertension and renal
artery arteriosclerosis increased 46% during the period of
study, from 1.5 cases to 2.2 per 100,000 adults (Fig 1, P
.001). Combined aortic and renal revascularization de-
creased 73%, from 0.12 to 0.03 per 100,000 adults (P 
.033), while isolated renal revascularization decreased 56%,
from 0.2 to 0.09 per 100,000 adults (P  .001). During
Fig 1. Cases per year per 100,000 adults. There has b
renovascular hypertension and renal artery atheroscleros
Fig 2. A 73% and 56% decline in combined aortic and r
P  .001) occurred over the 14-year study period. Angithis same period, angioplasty and stenting increased 173%,
from 0.4 to 1.1 per 100,000 adults (Fig 2, P .001). There
was a 67% increase in interventions in general during this
time period, from 0.73 to 1.22 per 100,000 adults (P 
.001).
Predictors of catheter-based intervention. When
comparing only isolated renal artery revascularization with
catheter-based intervention, angioplasty was more likely to
a 46% increase in discharges with a diagnosis code for
r the study period (P  .0002).
as well as isolated renal revascularizations (P .033 and
ty and stenting increased 173% (P  .001).eenenal,
oplas
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sions, older age, nonwhite race, and higher income (Table
II). Comorbidities and gender were not significant predic-
tors of the type intervention. Catheter-based interventions
occurred more frequently from 1998 to 2001 (P  .001)
and 1993 to 1997 (P  .001) compared with 1988 to
1992. There was a significant regional variation in the
proportion of patients undergoing catheter-based interven-
tion (Fig 3, P  .001).
In-hospital mortality. In-hospital mortality did not
significantly change over the 14-year period, with an overall
rate of 5.2% for combined aortic and renal revasculariza-
tion, 2.2% for isolated renal revascularization, and 0.8% for
angioplasty and stenting (Fig 4). In a multivariate analysis,
significant predictors of mortality included increasing age,
surgical intervention, emergent admission, and nonwhite
race (Table III). Median income, comorbidities, sex, and
time period were not significant predictors of mortality.
There was no significant regional variation in mortality
following any treatment type.
Length of stay. Mean LOS decreased significantly for
all 3 treatment groups (P  .001 for each). At all time
points, LOS was longest after aortic and renal revascular-
izations and shortest for catheter-based interventions (P 
.001; Fig 5). There were also significant regional variations
Fig 3. There was a significant regional variation in rates of percu-
taneous intervention for revascularization (P  .001).
Table II. Multivariate analysis of predictors of
angioplasty or stenting: Comparison between isolated
renal artery reconstruction versus angioplasty and stenting
Independent variable
Predictors of angioplasty
or stenting,
OR (95% CI) P
Emergent admission 3.5 (2.7-4.7) .001
Urgent admission 2.2 (1.8-2.8) .001
Age 77* 2.5 (1.9-3.3) .001
Age 71-76* 1.5 (1.2-1.9) .001
Nonwhite race 1.7 (1.2-2.4) .003
OR, Odds ratio.
*Compared with age 60 years.in LOS after aortic and renal revascularization, isolated
renal revascularization, and angioplasty and stenting (Fig 6;
P  .009, P  .001, and P  .004, respectively).
Hospital charges. Hospital charges did not change
significantly for surgical interventions over the 14-year
period of study, although catheter-based charges increased
61% (P  .001). At all time points, combined aortic and
renal revascularizations were associated with the highest
average hospital charges and catheter-based revasculariza-
tions with the lowest charges (P .001; Fig 7). There were
also significant regional variations in total hospital charges
following aortic and renal revascularization, isolated renal
revascularization, and angioplasty and stenting (Fig 8; P 
.001, P  .017, and P  .001, respectively).
Unfavorable discharge. In all treatment groups, rates
of unfavorable discharges to any location other than home
(excluding in-hospital mortality) increased significantly
with time (P  .002, P  .004, and P  .001) for
combined aortic and renal, isolated renal, and catheter-
based revascularizations, respectively (Fig 9). In a multivar-
iate analysis, predictors of an unfavorable discharge in-
cluded surgical intervention, increasing age, admission
Fig 4. In hospital mortality versus time. By 2 analysis, there were
no significant variations in mortality over time for any treatment
class.
Table III. Multivariate analysis of mortality:
Independent predictors of in-hospital mortality after
intervention for renovascular hypertension
Independent variable
Risk of mortality,
OR (95% CI) P
Age 75 years* 10.4 (2.3-46.0) .002
Age 68-74 years* 6.5 (1.5-28.7) .014
Age 60-67 years* 7.2 (1.6-32.1) .009
Combined surgical treatment† 8.2 (4.0-16.9) .001
Isolated renal revascularization† 4.1 (1.9-8.7) .001
Emergent Admission 3.9 (2.1-7.4) .001
Nonwhite race 3.1 (1.5-6.7) .004
OR, Odds ratio.
*Compared to age 59 years.
†Compared to angioplasty or stenting procedures.
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income and comorbidities were not significant predictors of
unfavorable discharges. There were also significant regional
variations in the incidence of unfavorable discharge after
aortic and renal revascularization and isolated renal revas-
cularization (Fig 10, P  .03 and P  .007, respectively).
DISCUSSION
The number of patients discharged from US hospitals
with a diagnosis of renal artery arteriosclerosis and renovas-
cular hypertension has increased significantly over the 14-
year period of this study. During this same period, there
was a 17% increase in the overall number of individuals over
the age of 65, from 30 million in 1988 to 35 million in
2001. Whereas the proportion of patients undergoing re-
vascularizations has remained essentially stable, the type of
intervention has dramatically shifted from open surgical
Fig 5. All treatment classes exhibited trends towards decreasing
length of stay (P  .001 for all groups). At all time points,
combined aortic and renal revascularization had the longest aver-
age length of stay, followed by isolated renal revascularization, and
then angioplasty and stenting (P  .001).
Fig 6. There were significant regional variations in mean length
of stay for patients undergoing aortic and renal reconstruction (P
 .009), isolated renal reconstruction (P .001), and angioplasty
and stenting (P  .004).revascularizations to catheter-based interventions. In addi-
tion, percutaneous catheter-based interventions are in-
creasingly associated with an older population and with
disease of a higher acuity. The association of nonwhite race
with increased likelihood of catheter-based intervention
may result from demographic characteristics of populations
near tertiary care centers where this technology is accessi-
ble.
Hospital charges have increased in the catheter-based
treatment group, reflecting the greater use of this technol-
ogy, and are approaching inpatient charges for isolated
renal revascularizations. It is notable that these charges do
not include radiographic studies commonly performed in
follow-up of these patients. In addition, these charges do
not include charges accompanying late failures. The poten-
tial exists for the cost of catheter-based therapy of renal
Fig 7. There were no significant trends in total hospital charges
for either combined aortic and renal or isolated renal surgical
repairs. Charges for angioplasty and stenting increased significantly
(P  .001), approaching charges for isolated surgical renal revas-
cularization. All costs were corrected for 4% annual inflation.
Fig 8. There were significant regional variations in total hospital
charges for patients undergoing aortic and renal reconstruction (P
 .001), isolated renal reconstruction (P .017), and angioplasty
and stenting (P  .001).
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cal repair.
LOS has decreased significantly in all treatment groups
despite trends towards poorer outcomes. It is possible that
the poorer outcomes observed in more recent years re-
flected increasing technical savvy and application of these
technologies to sicker patients, a likelihood supported by
the fact that the Romano-Charleson comorbidity index
increased significantly over the time period of the study
(data not shown). A confounding factor in LOS analysis
was the lack of information on length of time from admis-
sion to procedure. It was assumed that all procedures in this
study occurred at admission. However, LOS in this study
was similar to that cited by Xue et al (0.6 and 2.0 days for
renal angioplasty and stenting, respectively).16
Conventional renal revascularization procedures carry
the potential for significant morbidity and mortality, espe-
cially when combined with aortic reconstructions. The
Fig 9. All treatment classes exhibited a significant trend towards
increased risk of unfavorable discharge (P  .002 for aortic and
renal reconstruction, P .004 for isolated renal revascularization,
and P  .001 for angioplasty and stenting).
Table IV. Multivariate analysis of unfavorable discharge:
Independent predictors of discharge other than to home,
excluding in-hospital mortality after intervention for
renovascular hypertension
Independent variable
Risk of mortality,
OR (95% CI) P
Combined surgical treatment* 7.4 (5.3-10.3) .001
Isolated renal revascularization* 4.3 (3.2-5.9) .001
Age  75† 5.2 (3.5-7.6) .001
Age 68 to 74† 2.9 (2.0-4.3) .001
Age 60 to 67† 1.8 (1.2-2.8) .004
Emergent admission 3.6 (2.7-4.8) .001
Urgent admission 1.4 (1.1-1.8) .019
Nonwhite race 1.6 (1.1-2.3) .022
Female sex 1.3 (1.1-1.7) .014
OR, Odds ratio.
*Compared to angioplasty and stenting procedures.
†Compared to age 59 years.mortality of isolated catheter-based intervention is certainly
less than surgical repair. Nevertheless, serious complica-
tions may be associated with angioplasty and stenting,
perhaps related to the treatment of patients with more
extensive renal artery pathology. It is incumbent upon the
physician to carefully evaluate each particular patient and
choose therapy appropriate for that individual.
It is notable that there were significant regional varia-
tions in the rates of angioplasty and stenting, unfavorable
discharge, LOS, and hospital charges. However, there were
no significant variations in patient mortality. The basis for
this observation is unknown.
The NIS is an administrative database with several
limitations. During the study period, the NIS database
expanded from 8 to 33 states, and from 759 to 986
hospitals, with changes in sampling and weighting strate-
gies. There are a limited number of variables for each
discharge record, and it is not possible to identify particular
discharge records to track prior or subsequent hospitaliza-
tions. In addition, there is a recognized inaccuracy of the
database regarding errors in the primary diagnostic code on
Medicare claims forms.25 Comorbidity data may also be of
limited value for risk adjustment in the context of adminis-
trative data.26 Acute renal failure, for example, is a very
important clinical outcome, yet the coding process prevents
differentiation of preoperative and postoperative renal fail-
ure. Alterations in coding methods over the study period,
including ICD-9-CM changes or changes in the NIS data-
base itself, introduced potential for error into this study.
For example, prior to 1995, renal angioplasty and stenting
was coded as “other repair of vessels.” Therefore, an un-
known percentage of procedures which were assumed to be
renal artery interventions were in fact nonrenal procedures.
Nevertheless, correction of this error would further high-
light the tremendous increase in the rate of percutaneous
renal angioplasty and stenting in the United States,
strengthening our conclusion that there has been a major
shift in the management of renal artery stenotic disease.
Fig 10. There were significant regional variations in the rate of
unfavorable discharge for patients undergoing aortic and renal
reconstruction (P  .03) and isolated renal reconstruction (P 
.007).
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limited to inpatient data. As many of these procedures are now
performed on an outpatient basis,16 the patients in this study
undergoing percutaneous therapy are likely to be sicker or
were admitted for other reasons. In addition, it is notable that
there were significantly more patients admitted emergently or
urgently to the group undergoing catheter-based therapy
compared with the surgical treatment groups. One possible
explanation for this finding is that patients undergoing coro-
nary angiography for chest pain or heart failure have a high
incidence of incidentally noted renal artery stenoses2; patients
in this higher-acuity category would therefore be likely to
preferentially undergo renal artery interventions concomi-
tantly, leading to a heterogeneous study population. These
limitations may bias the outcomes of this study and, therefore,
conclusions regarding mortality, cost, and LOS should be
evaluated accordingly. Yet, administrative database limitations
are offset in studies such as the current one by strengths
including large patient volumes, hard clinical end points like
mortality, and an opportunity to evaluate practice trends
across all levels of practice.
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